Resectable pancreatic adenocarcinoma neo-adjuvant folf(irin)ox-based chemotherapy – a multicenter, non-comparative, randomized, phase ii trial (panache01-prodige48 study)

HIGHLIGHTS

• who: Lilian Schwarz and colleagues from the Department of Digestive Surgery, Hu00f4pital Charles Nicolle, Rouen, France UNIROUEN, UMR , INSERM, Rouen University Hospital, Department of have published the Article: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study), in the Journal: (JOURNAL)
• what: The aim of the trial is to evaluate the feasibility and efficacy of two regimens of neoadjuvant chemotherapy. CT scan: Patients eligible for this study have resectable PDAC as shown on CT scan of thorax, abdomen and pelvis with IV contrast . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.